WeChat· Best in Class·· 7 hours agoPickScore73
ESMO 2026: Qilu's QL1706 Posts 30.95-Month OS in Phase 3 First-Line Cervical Cancer
In brief
At ESMO 2026, Qilu Pharmaceutical reported phase 3 overall survival of 30.95 months for QL1706, a PD-1/CTLA-4 bispecific antibody, plus chemotherapy with or without bevacizumab as first-line treatment of persistent, recurrent or metastatic cervical cancer.
Why it matters
The brief gives the QL1706 phase 3 first-line cervical cancer OS readout of 30.95 months for comparison with other regimens.
Source: WeChat · mp.weixin.qq.com